MED | Nesbit Prize in Clinical Science awarded to Univ.-Prof. Dr. Milen Minkov
Univ.-Prof. Dr. Milen Minkov received the Nesbit Prize in Clinical Science on 28 September 2026 at the Annual Meeting of the Histiocyte Society in Rotterdam, the Netherlands. The prize recognizes his work “Preliminary results of the randomized trial for children with multisystem Langerhans cell histiocytosis (LCH) (Stratum I, Group 1 of the LCH-IV Study)”. The Histiocytosis Association and the Histiocyte Society award it every year for the best clinical research presented at the meeting. The Histiocyte Society is the leading international scientific body for histiocytic disorders, a group of rare and often puzzling diseases that mainly affect children. A special committee chooses the winner based on originality, completeness, scientific accuracy and contribution to science.
The award-winning work reports the first results of a large randomized trial in children whose LCH affects several organ systems. This form of the disease requires the most intensive treatment. LCH-IV was conducted in 24 countries on five continents and is the largest clinical trial ever conducted in LCH. Its results are expected to shape how children with multisystem LCH are treated worldwide.
The prize is named after Dr. Mark Nesbit of the University of Minnesota, a renowned pediatric hematologist-oncologist. He was a founding figure of the Histiocyte Society and a long-standing supporter of patients and families affected by histiocytosis.